PhVWP

Patients & Consumers Experience

Albert van der Zeijden Cristina Cabrita Greetje Goossens

PCWP, London, 28 February 2012

What is the PhVWP?

 Expert Group to the CHMP (Committee for Medicinal Products for Human Use)

• What is the aim?

- Investigate Adverse reactions of medicines authorized in EU
- Advice on the safety of medicines
- Support to CHMP to identify, assess and manage the risk of a medicine product

Composition of the PhVWP

- Chairperson (Dr. June Raine)
- 1 member per Member State, Norway, Iceland and Liechtenstein
- Co-opted members with specific expertise (eg. pharmacoepidemiology, statistics,...)
- Observers:
 - 1 European Commission
 - 2 patient observers
 - EMA staff

How it works?

- It always starts with a signal detection:
 - EudraVigilance
 - Database of NCA
 - Periodic safety reports
 - Scientific literature, other...

How it works

PhVWP

- analyses potential signals
- advises on confirmation and quantification of risk
- compares the risk to the benefit

If it is confirmation of a safety probem Measures are to be taken

Measures

- Activate the risk management plan, which could involve communication programs, educational programs for patients/consumers and or healthcare professionals;
- Change PIL and/or SPC;
- Direct Healthcare Professional Communication (DHPC);
- Suspend the medicine;
- Withdraw the medicine;
- Reduce the number of pills per package;
- Change the medicine status (OTC to prescription).

Patients&Consumers in the PhVWP

The goal:

- transparency of regulatory/pharmacovigilance activities towards the society
- to include patients' / consumers perspective in the regulatory activities, to make sure that decisions meet the needs
- → Connection between the regulatory world and the reality of patient care

Patients& Consumer role

- Patient& Consumer perspective in discussions, assessments and actions to be taken: questions and contribution
- Advice on communication strategy (content of communication, channels, target groups) e.g. DHPC
- Review of product information (PL, EPAR, SmPC), and ensure readability
- Discussion on policy and regulatory issues
- Connection with concerned patient groups

Patients& Consumer role

Ad Hoc:

- Drafting group on transparency and communication (elaboration on guidelines on risk communication)
- Drafting group on new PV-legislation
- Meetings with external stakeholders
- Involvement in external conferences/workshops

Example

- Web-educational-materials: are developed in a context of risk management plan, these
 materials are not harmonized and are of national competence. When a member state
 propose to have an harmonize view on this programs several suggestions were made and
 were contemplated one the draft proposal- Ongoing
- e.g.
- Say to whom is directed (target audience)
- Information should be unbiased, objective,
 - Information given should be in accordance with SPC and PIL and other data should be supported by clear references
- Competent authorities should always have passwords to access the content
- Patient/consumer data should be confidential
- This web-sites shouldn't have link to social networks as Facebook, or others like twitter even if this is push
- Measures to evaluate the program should be measurable



- Patients provide insight into new safety signals and risk assessments
- Patients improve the quality of product information
- Patients make a practical contribution to enhance the value of risk communication
- Patients provide inside knowledge of how to ensure risk communications reach the appropriate target audiences
- Patients input into strategic discussions on a wide range of topics from ADR reporting systems to drugs and driving

Dr. June Raine, Chair of the PhVWP

In Practice

- 3 days from Monday to Wednesday every month
- Constantly changing. Some 30 + items on particular medicines the first two days: signals, conclusions of assessment reports, CHMP questions, adoption of reports etc.
- Policy and regulatory affairs
- Side activities: Drafting groups, video-conference with FDA, working groups etc.
- One teleconference before the meeting


Impressions

- First meetings are complex and very intense, many issues, jargon, missing the context
 - Workload
 - Personal investement
 - Motivation

Considerations for the future

There is support but

 Manual to new comers to help them understand the regulatory framework, acronyms would be very useful



Thank you